Novavax shares jumped to start off the week after an update from its COVID-19 vaccine trial. This news adds to investor optimism and is helping to lift the broad markets in general.
Moderna made a big step towards a COVID-19 vaccine early on Monday, and investors (and the stock market in general) responded very positively.
Chris Lange Wednesday's top analyst upgrades and downgrades included Akamai Technologies, Carlyle, Ford, General Motors, JD.com, Moderna, Netflix, Peloton Interactive, Raytheon Technologies, Target, Tesla and Visa.
Biotech firm Inovio has begun Phase 1 trials of a new vaccine for COVID-19. The trial is beginning Monday.
Dynavax Technologies shares made a handy gain on Thursday after the company announced that it would be entering the coronavirus vaccine business. Is the market for these vaccines getting oversaturated?
24/7 Wall St. has tracked some health care companies with prospects at crafting a vaccine, treatment or test to deal with this coronavirus and here is where their stocks stand now.
24/7 Wall St. has tracked multiple S&P 500 and other large-cap stocks that actually closed up for the past week and that are also still higher year to date.
24/7 Wall St. has tracked some health care companies with prospects at crafting a vaccine, treatment or test to deal with this novel coronavirus. Here's how they fared as the week wound…
24/7 Wall St. has tracked some health care companies with prospects at crafting a vaccine to deal with this novel coronavirus and where they stand now.
In times like this, investors tend to move toward companies with rock-solid balance sheets and healthy dividends. These stocks were actually beating Monday’s sell-off and could offer long-term value for investors.
The February 28 short interest data have been compared with the previous figures, and short interest in most of these selected coronavirus stocks increased.
Thursday's top analyst upgrades, downgrades and initiations included Abbott Laboratories, Alexion Pharmaceuticals, Avis Budget, DexCom, Johnson & Johnson, Marvell Technology, Moderna, Snap, Splunk and Zoom Video Communications.
With more than 60,000 reported cases of the coronavirus and nearly 1,400 deaths worldwide along with quarantines and travel restrictions, the impact of the disease on global GDP is just beginning to…
Moderna Inc. (NASDAQ: MRNA) had been the biggest biotech initial public offering ever. The company was quite unlucky in the timing for its IPO, but it managed to get back into favor…
Jon C. Ogg As with almost all pandemic scares and other national and global issues, some speculative stocks manage to see their shares rise sharply.
